OBSOLETE: Sporadic secreting paraganglioma

Sporadic secreting paraganglioma (Orphanet code 276627) is an obsolete disease classification that was previously used to describe paragangliomas occurring without a known hereditary basis that actively produce and secrete catecholamines (such as epinephrine, norepinephrine, or dopamine). Paragangliomas are rare neuroendocrine tumors arising from extra-adrenal chromaffin cells of the autonomic nervous system, most commonly found in the head, neck, thorax, or abdomen. When these tumors are 'secreting,' they release excess catecholamines into the bloodstream, which can cause episodic or sustained hypertension, headaches, palpitations, excessive sweating, anxiety, and tremors — collectively resembling the symptoms of pheochromocytoma. This entry has been marked as OBSOLETE in Orphanet, meaning it is no longer considered a distinct clinical entity for classification purposes. Advances in genetic understanding have revealed that a significant proportion of previously considered 'sporadic' paragangliomas actually harbor germline mutations in susceptibility genes such as SDHB, SDHC, SDHD, TMEM127, MAX, and others. As a result, the distinction between sporadic and hereditary forms has been largely reclassified, and patients are now categorized under more specific genetic or clinical subtypes. Treatment for secreting paragangliomas generally includes surgical resection as the primary approach, with preoperative alpha-adrenergic blockade to manage catecholamine-related cardiovascular risks. For metastatic or unresectable cases, options may include radionuclide therapy (such as 131I-MIBG), chemotherapy, or targeted therapies. Lifelong biochemical and imaging surveillance is recommended due to the risk of recurrence or metastasis.

Common questions about OBSOLETE: Sporadic secreting paraganglioma